Информация предназначена только для профессионалов в области здравоохранения.
Вы можете зайти как пользователь социальных сетей
ФГАОУ ВО «Первый Московский государственный медицинский университет им. И.М.Сеченова» Минздрава России. 119991, Россия, Москва, ул. Трубецкая, д. 8, стр. 2
Список исп. литературыСкрыть список 1. Wittchen HU, Jacobi F, Rehm J et al. The size and burden of mental disorders and other disorders of the brain in Europe 2010. Eur Neuropsycho-pharmacol 2011; 21: 655–79. 2. Kessler RC. The global burden of anxiety and mood disorders: putting the European Study of the Epidemiology of Mental Disorders (ESEMeD) findings into perspective. J Clin Psychiatry 2007; 68 (Suppl. 2): 10–9. 3. Altemus M, Sarvaiya N, Neill Epperson C. Sex differences in anxiety and depression clinical perspectives. Front Neuroendocrinol 2014; 35: 320–30. 4. Тювина Н.А., Балабанова В.В., Воронина Е.О. Гендерные особенности депрессивных расстройств у женщин. Журн. неврология, нейропсихиатрия и психосоматика. 2015; 7 (2): 75–8. / Tiuvina N.A., Balabanova V.V., Voronina E.O. Gendernye osobennosti depressivnykh rasstroistv u zhenshchin. Zhurn. nevrologiia, neiropsikhiatriia i psikhosomatika. 2015; 7 (2): 75–8. [in Russian] 5. Silverstein B, Edwards T, Gamma A et al. The role played by depression associated with somatic symptomatology in accounting for the gender difference in the prevalence of depression. Soc Psychiatry Psychiatr Epidemiol 2013; 48 (2): 257–63. DOI: 10.1007/s00127-012-0540-7. 6. Тювина Н.А., Балабанова В.В., Воронина Е.О. Депрессии у женщин, манифестирующие в период климактерия. Журн. неврологии и психиатрии им. С.С.Корсакова. 2017. / Tiuvina N.A., Balabanova V.V., Voronina E.O. Depressii u zhenshchin, manifestiruiushchie v period klimakteriia. Zhurn. nevrologii i psikhiatrii im. S.S.Korsakova. 2017. [in Russian] 7. Kornstein SG. Evaluation and management of depression in women across the life span. J Clin Psychiatry 2001; 62 (Suppl. 24): 11–7. 8. Wu X, de Maris A. Gender and marital status differences in depression: the effects of chronic strains. Sex Roles 1996; 34: 299–319. 9. Kupers TA. Men at work and out of work. Psychiatr Ann 1996; 26: 29–32. 10. Sargeant JK, Bruce ML, Florio LP et al. Factors associated with 1-year outcome of major depression in the community. Arch Gen Psychiatry 1990; 47: 519–26. 11. Ernst C, Angst J. The Zurich Study, XII, sex differences in depression: evidence from longitudinal epidemiological data. Eur Arch Psychiatry Clin Neurosci 1992; 241: 222–30. 12. Angst J, Dobler-Mikola A. Do the diagnostic criteria determine the sex ratio in depression? J Affect Dis 1984; 7: 189–98. 13. Halbreich U, Kahn LS. Atypical depression, somatic depression and anxious depression in women: are they gender-preferred phenotypes? J Affect Dis 2007; 102 (1–3): 245–58. 14. Moskvina V, Farmer A, Jones IR et al. Sex differences in symptom patterns of recurrent major depression in siblings. Depress Anxiety 2008; 25 (6): 527–34. 15. Lai CH. Major depressive disorder: gender differences in symptoms, life quality, and sexual function. J Clin Psychopharmacol 2011; 31 (1): 39–44. DOI: 10.1097/JCP.0b013e318205a670. 16. Frank E, Carpenter LL, Kupfer DJ. Sex differences in recurrent depression: are there any that are significant? Am J Psychiatry 1988; 145: 41–5. 17. Kennedy SH. Treating each and every depressed patient. J Psychopharmacol 2008; 22 (Suppl. 7): 19–23. 18. Kornstein SG, Sloan MD, Thase ME. Gender-specific differences in depression and treatment response. Psychopharmacol Bull 2002; 36 (4 Suppl. 3): 99–112. 19. Simoni-Wastila L. Gender and psychotropic drug use. Medical Care 1998; 36: 88–94. 20. Kornstein SG, Wojcik BA. Gender effects in the treatment of depression. Psychiatr Clin North Am Ann Drug Ther 2000; 7: 23–57. 21. Kokras N, Dalla C. Preclinical sex differences in depression and antidepressant response: implications for clinical research. J Neurosci Res 2017; 95: 731–6. 22. Hamilton JA, Yonkers KA. Sex differences in pharmacokinetics of psychotropic medications, part I: biological basis for effects. In: Jensvold MF, Halbreich U, Hamilton JA, eds. Psychopharmacology and Women: Sex, Gender and Hormones. Washington, DC: American Psychiatric Press, 1996; p. 11–42. 23. Kornstein SG, Schatzberg AF, Thase ME et al. Gender differences in treatment response to sertraline versus imipramine in chronic depression. Am J Psychiatry 2000; 157: 1445–52. 24. Hamilton JA, Grant M, Jensvold MF. Sex and treatment of depression: when does it matter? In: Jensvold MF, Halbreich U, Hamilton JA, eds. Psychopharmacology and Women: Sex, Gender, and Hormones. Washington, DC: American Psychiatric Press, 1996; p. 241–57. 25. Davidson J, Pelton S. Forms of atypical depression and their response to antidepressant drugs. Psychiatry Res 1986; 17: 87–95. 26. Halbreich U, Rojansky N, Palter S et al. Estrogen augments serotonergic activity in postmenopausal women. Biol Psychiatry 1995; 37: 434–41. 27. Thase ME, Frank E, Kornstein SG, Yonkers KA. Gender differences in response to treatments of depression, in Gender and Its Effects on Psychopathology. Ed. by Frank E. Washington, DC, American Psychiatric Association Press, 2000; p. 103–29. 28. Kornstein SG. Gender differences in depression: implications for treatment. J Clin Psychiatry 1997; 58 (Suppl. 15): 12–8. 29. Quitkin FM, Stewart JW, McGrath PJ et al. Columbia atypical depression: a subgroup of depressives with better response to MAOI than to tricyclic antidepressants or placebo. Br J Psychiatry (Suppl.) 1993; 21: 30–4. 30. Pande A, Birkett M, Fechner-Bates S et al. Fluoxetine versus phenelzine in atypical depression. Biol Psychiatry 1996; 40: 1017–20. 31. Steiner M, Wheadon DE, Kreider MS, Bushnell WD. Antidepressant response to paroxetine by gender, in 1993 Annual Meeting New Research Program and Abstracts. Washington, DC, American Psychiatric Association, 1990; p. 176. 32. Lewis-Hall FC, Wilson MG, Tepner RG, Koke SC. Fluoxetine vs tricyclic antidepressants in women with major depressive disorder. J Womens Health 1997; 6: 337–43. 33. Entsuah R, Huang H, Thase ME. Response and remission rates in different subpopulations with major depressive disorder administered venlafaxine, selective serotonin reuptake inhibitors, or placebo. J Clin Psychiatry 2001; 62: 869–77. 34. Kasper S et al. Antidepressant efficacy of agomelatin versus SSRI/SNRI: results from a pooled analysis of head-to-head studies without a placebo control. Int Clin Psychopharmacol 2013; 28: 12–9. 35. Taylor D et al. Antidepressant efficacy of agomelatin : meta-analysis of published and unpublished studies – 2014. 36. Khoo AL et al. Network meta-analysis and cost-effectiveness analysis of new generation antidepressants. CNS drugs 2015; 29 (8): 695–712. 37. Тювина Н.А. Депрессия у женщин. М.: Сервье, 2006. / Tiuvina N.A. Depressiia u zhenshchin. M.: Serv'e, 2006. [in Russian] 38. Endicott J. History, evolution, and diagnosis of premenstrual dysphoric disorder. J Clin Psychiatry 2000; 61(Suppl. 12): 5–8. 39. Ross L, Steiner M. A biopsychosocial approach to premenstrual dysphoric disorder. Psychiatr Clin North Am 2003; 26: 529–46. 40. Yonkers K. The association between premenstrual dysphoric disorder and other mood disorders. J Clin Psychiatry 1997; 58 (Suppl. 15): 19–25. 41. Cohen L, Soares C, Otto M et al. Prevalence and predictors of premenstrual dysphoric disorder (PMDD) in older premenopausal women. The Harvard Study of Moods and Cycles. J Affect Disord 2002; 70: 125–32. 42. Pearlstein T, Frank E, Rivera-Tovar A et al. Prevalence of axis I and axis II disorders in women with late luteal phase dysphoric disorder. J Affect Disord 1990; 20: 129–34. 43. Pariser S, Nasrallah H, Gardner D. Postpartum mood disorders: clinical perspectives. J Womens Health 1997; 6: 421–34. 44. Halbreich U, Bergeron R, Yonkers K et al. Efficacy of intermittent, luteal phase sertraline treatment of premenstrual dysphoric disorder. Obstet Gynecol 2002; 100: 1219–29. 45. Cohen L, Miner C, Brown E et al. Premenstrual daily fluoxetine for premenstrual dysphoric disorder: a placebo-controlled, clinical trial using computerized diaries. Obstet Gynecol 2002; 100: 435–44. 46. Miner C, Brown E, McCray S et al. Weekly luteal-phase dosing with enteric-coated fluoxetine 90 mg in premenstrual dysphoric disorder: a randomized, double-blind, placebo-controlled clinical trial. Clin Ther 2002; 24: 417–33. 47. Freeman E, Rickels K, Yonkers K et al. Venlafaxine in the treatment of premenstrual dysphoric disorder. Obstet Gynecol 2001; 98: 737–44. 48. Hunter M, Ussher J, Browne S et al. A randomized comparison of psychological (cognitive behavior therapy), medical (fluoxetine) and combined treatment for women with premenstrual dysphoric disorder. J Psychosom Obstet Gynaecol 2002; 23: 193–9. 49. Bolton H, Hughes P, Turton P, Sedgwick P. Incidence and demographic correlates of depressive symptoms during pregnancy in an inner London population. J Psychosom Obstet Gynaecol 1998; 19: 202–9. 50. O’Hara M. Social support, life events, and depression during pregnancy and the puerperium. Arch Gen Psychiatry 1986; 43: 569–73. 51. O’Hara M. Depression during pregnancy. Postpartum depression: causes and consequences. New York: Springer-Verlag, 1994; p. 110–20. 52. Gotlib I, Whiffen V, Mount J et al. Prevalence rates and demographic characteristics associated with depression in pregnancy and the postpartum. J Consult Clin Psychol 1989; 57: 269–74. 53. Henshaw S. Unintended pregnancy in the United States. Fam Plann Perspect 1998; 30: 24–9, 46. 54. Steer R, Scholl T, Hediger M, Fischer R. Self-reported depression and negative pregnancy outcomes. J Clin Epidemiol 1992; 45: 1093–9. 55. Orr S, Miller C. Maternal depressive symptoms and the risk of poor pregnancy outcome. Review of the literature and preliminary findings. Epidemiol Rev 1995; 17: 165–71. 56. Zuckerman B, Bresnahan K. Developmental and behavioral consequences of prenatal drug and alcohol exposure. Pediatr Clin North Am 1991; 38: 1387–406. 57. Pritchard C. Depression and smoking in pregnancy in Scotland. J Epidemiol Community Health 1994; 48: 377–82. 58. Paton S, Kessler R, Kandel D. Depressive mood and adolescent illicit drug use: a longitudinal analysis. J Genet Psychol 1977; 131: 267–89. 59. Kielholz P. Alcohol and depression. Br J Addict Alcohol Other Drugs 1970; 65: 187–93. 60. Zuckerman B, Amaro H, Bauchner H, Cabral H. Depressive symptoms during pregnancy: relationship to poor health behaviors. Am J Obstet Gynecol 1989; 160: 1107–11. 61. Altshuler L, Cohen L, Moline M et al. The Expert Consensus Guideline Series. Treatment of depression in women. Postgrad Med 2001: 1–107. 62. Physician’s Desk Reference. Montvale (NJ): Medical Economics Company, 2000. 63. Ericson A, Kallen B, Wiholm B. Delivery outcome after the use of antidepressants in early pregnancy. Eur J Clin Pharmacol 1999; 55: 503–8. 64. Chambers C, Johnson K, Dick L et al. Birth outcomes in pregnant women taking fluoxetine. N Engl J Med 1996; 335: 1010–5. 65. Simon G, Cunningham M, Davis R. Outcomes of prenatal antidepressant exposure. Am J Psychiatry 2002; 159: 2055–61. 66. Goldstein D, Corbin L, Sundell K. Effects of first-trimester fluoxetine exposure on the newborn. Obstet Gynecol 1997; 89: 713–8. 67. Addis A, Koren G. Safety of fluoxetine during the first trimester of pregnancy: a meta-analytical review of epidemiological studies. Psychol Med 2000; 30: 89–94. 68. Stiskal J, Kulin N, Koren G et al. Neonatal paroxetine withdrawal syndrome. Arch Dis Child Fetal Neonatal Educ 2001; 84: F134–F135. 69. Laine K, Heikkinen T, Ekblad U, Kero P. Effects of exposure to selective serotonin reuptake inhibitors during pregnancy on serotonergic symptoms in newborns and cord blood monoamine and prolactin concentrations. Arch Gen Psychiatry 2003; 60: 720–6. 70. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed. Washington (DC): American Psychiatric Association, 1994. 71. Josefsson A, Berg G, Nordin C, Sydsjo G. Prevalence of depressive symptoms in late pregnancy and postpartum. Acta Obstet Gynecol Scand 2001; 80: 251–5. Полный список литературы можно посмотреть на нашем сайте в Интернете: www.con-med.ru